In our study of patients with advanced or metastatic CRPC, MSS CRC, and PD-(L)1–refractory NSCLC, the ORR associated with the combination of navarixin plus pembrolizumab was lower than that previously reported in patients treated with pembrolizumab monotherapy. This evidence concerns the gene CD274 and colorectal carcinoma.